journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/29721364/audio-recording-for-independent-confirmation-of-clinical-assessments-in-generalized-anxiety-disorder
#1
Steven D Targum, Christopher Murphy, Jibran Khan, Laura Zumpano, Mark Whitlock, Arthur A Simen, Brendon Binneman
Objective : The assessment of patients with generalized anxiety disorder (GAD) to deteremine whether a medication intervention is necessary is not always clear and might benefit from a second opinion. However, second opinions are time consuming, expensive, and not practical in most settings. We obtained independent, second opinion reviews of the primary clinician's assessment via audio-digital recording. Design : An audio-digital recording of key site-based assessments was used to generate site-independent "dual" reviews of the clinical presentation, symptom severity, and medication requirements of patients with GAD as part of the screening procedures for a clinical trial (ClinicalTrials...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707426/is-electroconvulsive-therapy-a-treatment-for-depression-following-traumatic-brain-injury
#2
Anja Srienc, Puneet Narang, Simrat Sarai, Yee Xiong, Steven Lippmann
Traumatic brain injury (TBI) can be caused by blunt or penetrating injury to the head. The pathophysiological evolution of TBI involves complex biochemical and genetic changes. Common sequelae of TBI include seizures and psychiatric disorders, particularly depression. In considering pharmacologic interventions for treating post-TBI depression, it is important to remember that TBI patients have a higher risk of seizures; therefore, the benefits of prescribing medications that lower the seizure threshold need to be weighed against the risk of seizures...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707425/psychosis-in-a-child-with-atypical-autism-a-case-report-and-a-brief-review-of-the-association-of-psychosis-and-autism
#3
Swapnajeet Sahoo, Susanta Kumar Padhy, Neha Singla, Aakanksha Singh
Recent studies have shown that individuals with an autism spectrum disorder (ASD) are at an increased risk of developing psychosis. Diagnosing psychosis in such individuals can be challenging when they present with symptoms at a young age. A careful history and thorough assessment are essential for proper diagnosis to avoid mislabeling certain behavioral problems encountered among children with ASD. We present the case of a 12-year-old child with atypical autism who developed psychotic symptoms that led to a diagnostic dilemma...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707424/comorbid-insomnia-and-psychiatric-disorders-an-update
#4
REVIEW
Khurshid A Khurshid
Insomnia is a clinical problem of significant public health importance. Insomnia can be a symptom or harbinger of other psychiatric disorders. Insomnia can also be comorbid with other psychiatric disorders, thereby adding to the medical burden and increasing the risk of psychiatric relapse. Insomnia can also be associated with medical and neurological disorders. Some medications can also cause insomnia. Treatment of insomnia can lead to positive outcomes, not only by alleviating symptoms and moderating these comorbid disorders, but by preventing new episodes...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707423/effects-of-statins-and-cholesterol-on-patient-aggression-is-there-a-connection
#5
Emily Leppien, Kimberly Mulcahy, Tammie Lee Demler, Eileen Trigoboff, Lewis Opler
Overview : Psychiatric adverse effects, including aggression, have been reported with the use of statin medications; however, there is little data to support or refute the theory that statins or low serum cholesterol do in fact increase a patient's risk of aggression. Objective : This study examined 1) statin use and increased aggression, measured by the requirement of either emergent psychiatric intervention referred to as "Code Green" (CG) or "Restraint and Seclusion" (RS) and 2) cholesterol level and increased aggression in psychiatric inpatients...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707422/modafinil-for-the-improvement-of-patient-outcomes-following-traumatic-brain-injury
#6
REVIEW
Amne Borghol, Michael Aucoin, Ifeanyichukwu Onor, Dana Jamero, Fadi Hawawini
Objective : The authors sought to assess the literature evidence on the efficacy of modafinil use in patients with fatigue or excessive daytime sleepiness (EDS) secondary to traumatic brain injury (TBI). Method of Research : A literature search of Medline and PubMed was performed using the EBSCOhost database. Primary literature, observational studies, meta-analyses, case reports, and systematic reviews were assessed for content regarding modafinil and psychostimulant use in patients with TBI. Of the 23 articles collected, three randomized, controlled studies, three observational studies, one case report, and two systematic reviews gave a description of modafinil use in TBI patients...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707421/neuroscience-is-the-next-oncology
#7
EDITORIAL
Michael D Ehlers
No abstract text is available yet for this article.
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707420/prolactin-levels-in-patients-with-schizophrenia-who-were-switched-from-daily-to-once-monthly-aripiprazole-treatment
#8
Masaru Nakamura, Takahiko Nagamine
No abstract text is available yet for this article.
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707419/olanzapine-and-diabetic-ketoacidosis-what-is-the-underlying-mechanism
#9
Takahiko Nagamine
No abstract text is available yet for this article.
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707418/discussing-ant1-role-in-amyotrophic-lateral-sclerosis-pathogenesis
#10
Simona Portaro, Vincenzo Cimino, Antonino Naro, Rocco Salvatore Calabrò
No abstract text is available yet for this article.
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497580/wants-talk-psychotherapy-but-cannot-talk-emdr-for-post-stroke-depression-with-expressive-aphasia
#11
Jeffrey Guina, Cathryn Guina
While post-stroke depression (PSD) is a common sequelae of stroke, many stroke survivors also have expressive aphasia (i.e., the inability to produce spoken or written language), which limits or prevents treating depression with talk psychotherapy. Unlike most psychotherapy modalities, eye movement desensitization and reprocessing (EMDR) does not require extensive verbal communication to therapists, which might make EMDR an ideal treatment modality for aphasic patients with mental health concerns. The authors present the first known case reporting EMDR in aphasia, describing the treatment of a 50-year-old woman with a history of depression following a left middle cerebral artery stroke...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497579/cognitive-impairment-associated-with-cancer-a-brief-review
#12
REVIEW
J Cara Pendergrass, Steven D Targum, John E Harrison
This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497578/the-benefit-of-mirtazapine-in-the-treatment-of-progressive-multifocal-leukoencephalopathy-in-a-young-hiv-positive-patient-a-case-report
#13
Carola Mullins, Jorge Miranda, Hugo Sandoval, Luis Ramos-Duran, Silvina B Tonarelli
Highly active antiretroviral therapy is well-established in the treatment of human immunodeficiency virus (HIV)-positive patients. Nonadherence with therapy regimens often leads to the occurrence of opportunistic infections that further complicate treatment and challenge the treating physician. We report a young HIV-positive patient who suffered from progressive multifocal leukoencephalopathy caused by the human John Cunningham virus and showed objective clinical improvement after adding mirtazapine to the treatment regimen, an observation that is supported by the emerging literature...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497577/lower-extremity-dynamometry-as-a-novel-outcome-measure-in-a-double-blind-placebo-controlled-feasibility-trial-of-intravenous-immunoglobulin-ivig-for-hiv-associated-myelopathy
#14
Jessica Robinson-Papp, Mary Catherine George, Alexandra Nmashie, Donald Weisz, David M Simpson
Objective : Open-label data suggest that intravenous immunoglobulin (IVIG) might improve lower-extremity strength in human immunodeficiency virus (HIV)-associated myelopathy (HIVM), a rare but debilitating neurologic complication of HIV. We sought to determine the feasibility of testing the efficacy of IVIG for HIVM more rigorously. Design : We conducted a randomized, double-blind, placebo-controlled feasibility trial of IVIG for HIVM, using dynamometry as an outcome measure (Clinical Trial No. NCT01561755)...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497576/effectiveness-of-electroconvulsive-therapy-ect-in-parkinsonian-symptoms-a-case-series
#15
Sandeep Grover, Aditya Somani, Neeru Sahni, Sahil Mehta, Swati Choudhary, Rahul Kumar Chakravarty, Anju Moni Rabha
Depression is a common comorbidity in patients suffering from Parkinson's disease (PD). Available evidence suggests that electroconvulsive therapy (ECT) is an effective treatment for depression and also improves symptoms of PD. However, literature on usefulness of ECT in parkinsonian symptoms is limited. A review of records of all patients receiving ECT from 2010 to April 2017 in the authors' clinic yielded six cases (0.63% of all patients who received ECT at the authors' center over last 7 years) of depression with PD who were treated with ECT...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497575/pimavanserin-a-novel-drug-approved-to-treat-parkinson-s-disease-psychosis
#16
REVIEW
Amanda K Kitten, Sarah A Hallowell, Stephen R Saklad, Kirk E Evoy
Objective : Pimavanserin is the first United States Food and Drug Administration (FDA)-approved treatment for Parkinson's disease psychosis (PDP). This article reviews the safety, efficacy, and pharmacology data for pimavanserin and its role in therapy. Method of Research: Initial literature sources were identified via MEDLINE search (1946-September 2016) of pimavanserin and ACP-103 (original molecular designation). Reference review and search of FDA.gov and clinicaltrials.gov yielded additional studies. English-language studies of pimavanserin for PDP were evaluated...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29497574/stroke-telerehabilitation-in-sicily-a-cost-effective-approach-to-reduce-disability
#17
Alessia Bramanti, Alfredo Manuli, Rocco Salvatore Calabrò
No abstract text is available yet for this article.
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29410941/positive-and-negative-syndrome-scale-panss-training-challenges-solutions-and-future-directions
#18
REVIEW
Mark G A Opler, Christian Yavorsky, David G Daniel
Rater training and the maintenance of the consistency of ratings are critical to ensuring reliability of study measures and sensitivity to changes in the course of a clinical trial. The Positive and Negative Syndrome Scale (PANSS) has been widely used in clinical trials of schizophrenia and other disorders and is considered the "gold standard" for assessment of antipsychotic treatment efficacy. The various features associated with training and calibration of this scale are complex, reflecting the intricacy and heterogeneity of the disorders that the PANSS is used to evaluate...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29410940/are-shorter-versions-of-the-positive-and-negative-syndrome-scale-panss-doable-a-critical-review
#19
REVIEW
Jean-Pierre Lindenmayer
The Positive and Negative Syndrome Scale (PANSS) is a well-established assessment tool for measuring symptom severity in schizophrenia. Researchers and clinicians have been interested in the development of a short version of the PANSS that could reduce the burden of its administration for patients and raters. The author presents a comprehensive overview of existing brief PANSS measures, including their strengths and limitations, and discusses some possible next steps. There are two available scales that offer a reduced number of original PANSS items: PANSS-14 and PANSS-19; and two shorter versions that include six items: Brief PANSS and PANSS-6...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29410939/bridging-the-measurement-gap-between-research-and-clinical-care-in-schizophrenia-positive-and-negative-syndrome-scale-6-panss-6-and-other-assessments-based-on-the-simplified-negative-and-positive-symptoms-interview-snapsi
#20
EDITORIAL
Søren D Østergaard, Mark G A Opler, Christoph U Correll
There is currently a "measurement gap" between research and clinical care in schizophrenia. The main reason behind this gap is that the most widely used rating scale in schizophrenia research, the 30-item Positive and Negative Syndrome Scale (PANSS), takes so long to administer that it is rarely used in clinical practice. This compromises the translation of research findings into clinical care and vice versa. The aim of this paper is to discuss how this measurement gap can be closed. Specifically, the main points of discussion are 1) the practical problems associated with using the full 30-item PANSS in clinical practice; 2) how the brief, six-item version of the Positive and Negative Syndrome Scale (PANSS-6) was derived empirically from the full 30-item PANSS and what the initial results obtained with PANSS-6 entail; and 3) how PANSS-6 ratings, guided by the newly developed, 15-25-minute, stand-alone Simplified Negative and Positive Symptoms Interview (SNAPSI), might help bridge the measurement gap between research and clinical care in schizophrenia...
December 1, 2017: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"